Fundraising FoxAN Venture Partners
Venture capitalActively deployingTokyo · Seed–Growth · 22 people tracked
Also known as ANV MANAGEMENT, LLC
Find your way into AN Venture Partners
Sign up to see every warm intro you have to AN Venture Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AN Venture Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
AN Venture Partners invests in science-driven startups, with a strong emphasis on biotechnology and therapeutics. The firm positions itself as advancing Japanese biotech globally, leveraging an experienced core team and a global network of scientific experts. Its portfolio centers on early-stage life science ventures developing novel drug modalities such as small molecule therapies, RNA-based gene writing, siRNA engineering, and treatments for cardiometabolic, neurological, and rare diseases.
Source: firm website, verified Sep 27, 2026.
Team · 22 people
from the firm's website & curated
Founder mafia
2 people who came through AN Venture Partners went on to found or lead other companies.
What they invest in
from 9 of 12 portfolio companiesBiotech ×8Healthtech ×4Deep Tech ×2Medical Devices ×2AI & Machine Learning ×1Construction Tech ×1Data & Infrastructure ×1Digital Health ×1
HQs:United States×5Japan×1
Investments · 12 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 22022 · 14 dated
PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).
BiotechHealthtech
Co-investorsRA CapitalUTEC
Arterial automates roadway asset inventory, inspection, and condition assessment by passively collecting data from vehicles already driving a network, detecting and ranking infrastructure problems like potholes for public agencies.
AI & Machine LearningConstruction TechData & InfrastructureGovTechMobility & TransportationBoulder, US
Co-investorsTechstarsRA Capital
Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.
BiotechDeep TechLongevityPalo Alto, US
Amy Wang(PhD)inKenneth Horne(Executive Officer, Director)inDylan Morris(Director)inCristina Ghenoiu(Director)in
BoardTaro Inaba(Director)in
Co-investorsRemiges Ventures, Inc.Insight PartnersRA CapitalRDiscovery
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsARCH Venture PartnersSofinnova VenturesViking GlobalAltitude Ventures Management, LlcCasdin CapitalFidelity Investments+5 more
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsFrazier Life SciencesLightstone VenturesLongwood Fund
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)inAlbert M. Kim(Chief Medical Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalSanofi VenturesSV Health InvestorsCatalio Capital Management
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsCure VenturesThe Column Group
Typewriter Therapeutics develops mRNA-based gene therapies using a platform for targeted insertion of therapeutic genes, building on transposon research from the University of Tokyo.
BiotechDeep TechHealthtechTokyo, JP
Jun Zhou, PhD(Founder & Vice President, Discovery and Global Operations)Haruhiko Fujiwara, PhD(Founder & Advisor · Professor Emeritus, University of Tokyo)Tom Eickbush, PhD(Co-founder & Advisor · Professor Emeritus, University of Rochester)Kei Endo, PhD(Co-founder & Advisor · Associate Professor, University of Tokyo)Jim Collins, PhD(Co-founder & Advisor - Professor, MIT)Matthew Stanton, PhD(Chief Executive Officer)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Crystalys TherapeuticsPAhR TherapeuticsTortugas NeuroscienceTypewriter Therapeutics
Portfolio news
latest coverage across their companiesCity Therapeutics · finsmes.com · Jun 9, 2026
Imbria · finsmes.com · Nov 19, 2025
Frequently asked questions
- How many investments has AN Venture Partners made?
- AN Venture Partners has 12 tracked investments, including 2 dated in the last 24 months.
- What stage does AN Venture Partners invest at?
- AN Venture Partners invests at the Seed, Series A, Series B, Growth stages.
- What sectors does AN Venture Partners focus on?
- AN Venture Partners focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is AN Venture Partners located?
- AN Venture Partners is headquartered in Tokyo, JP.
- Does AN Venture Partners lead rounds?
- AN Venture Partners typically participates in rounds rather than leading them.
- Who does AN Venture Partners co-invest with?
- AN Venture Partners most often shares deals with RA Capital, Cure Ventures, Lightstone Ventures, among 14 tracked co-investors.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.